Erythema gyratum repens

Revision as of 20:37, 24 June 2019 by Hudakarman (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Erythema gyratum repens

Articles

Most recent articles on Erythema gyratum repens

Most cited articles on Erythema gyratum repens

Review articles on Erythema gyratum repens

Articles on Erythema gyratum repens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erythema gyratum repens

Images of Erythema gyratum repens

Photos of Erythema gyratum repens

Podcasts & MP3s on Erythema gyratum repens

Videos on Erythema gyratum repens

Evidence Based Medicine

Cochrane Collaboration on Erythema gyratum repens

Bandolier on Erythema gyratum repens

TRIP on Erythema gyratum repens

Clinical Trials

Ongoing Trials on Erythema gyratum repens at Clinical Trials.gov

Trial results on Erythema gyratum repens

Clinical Trials on Erythema gyratum repens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythema gyratum repens

NICE Guidance on Erythema gyratum repens

NHS PRODIGY Guidance

FDA on Erythema gyratum repens

CDC on Erythema gyratum repens

Books

Books on Erythema gyratum repens

News

Erythema gyratum repens in the news

Be alerted to news on Erythema gyratum repens

News trends on Erythema gyratum repens

Commentary

Blogs on Erythema gyratum repens

Definitions

Definitions of Erythema gyratum repens

Patient Resources / Community

Patient resources on Erythema gyratum repens

Discussion groups on Erythema gyratum repens

Patient Handouts on Erythema gyratum repens

Directions to Hospitals Treating Erythema gyratum repens

Risk calculators and risk factors for Erythema gyratum repens

Healthcare Provider Resources

Symptoms of Erythema gyratum repens

Causes & Risk Factors for Erythema gyratum repens

Diagnostic studies for Erythema gyratum repens

Treatment of Erythema gyratum repens

Continuing Medical Education (CME)

CME Programs on Erythema gyratum repens

International

Erythema gyratum repens en Espanol

Erythema gyratum repens en Francais

Business

Erythema gyratum repens in the Marketplace

Patents on Erythema gyratum repens

Experimental / Informatics

List of terms related to Erythema gyratum repens

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Gammel's disease.


Overview

Historical Perspective

  • In 1925 Rothman wrote a comprehensive review on the subject of cutaneous manifestations in patients with malignant tumors and since then cases were added to proof for the relationship between internal neoplasm and some skin lesions.
  • In 1953, the dermatologist, Dr. John A Gammel who was trained to link bizarre or recalcitrant dermatoses to internal diseases was the first one who described and labeled Erythema Granulatum Repens in a 55-year-old patient who had been complaining of pruritic scaly skin eruption and found few months later to have poorly differentiated adenocarcinoma
  • Up to 1992, there were only 49 cases in the literature, 41 of which (84%) were associated with a neoplasm
  • EGR is associated with internal malignancy in 82% of cases. However, between 1990 and 2010, data was collected from the medical records of patients form dermatology department in University of Genoa and from databases as pubmed and medline, the conclusion of this literature review was that EGR is no longer considered as an obligate paraneoplastic syndrome. More than expected cases of EGR were found with no neoplasm association

Classification

  • There is no established system for the classification of EGR. However, we can classify erythema gyratum repens based on its association with malignancy as:
    • Paraneoplastic EGR
    • Non-paraneoplastic EGR could be:
      • Idiopathic EGR
      • EGR-like eruptions (different dermatologic lesions that mimic EGR)
      • EGR with concomittant skin disease as:
        • pityriasis rubra pilaris, psoriasis, ichthyosis, CREST, rheumatoid arthritis, tuberculosis, bullous pemphigoid, linear IgA disease, and hypereosinophilic syndrome
      • Drug-induced EGR examples are:
        • Azathioprine with type I autoimmune hepatitis
        • Interferon given for hepatitis C virus–related chronic hepatitis


Erythema Gyratum Repens classification
Paraneoplastic erythema gyratum repens
Non-paraneoplastic erythema gyratum repens
Idiopathic EGR
EGR-like eruptions
EGR with concomittant skin disease
Drug-induced EGR

Pathophysiology

  • The cause of EGR has not been identified.
  • Many theories suggest that EGR is due to immunologic mechanisms. The immunologic mechanism theory is evidenced by the observed immunofluorescence patterns of IgG, C3, and C4 at the basement membrane:
    • Theory 1 the tumor induces antibodies that cross-react with the basement membrane of skin
    • Theory 2 the tumor produces polypeptides that bind skin antigens and render them immunogenic 
    • Theory 3 deposition of tumor antigen-antibody complexes onto the basement membrane causes reactive dermatitis seen in EGR


Causes

  • The cause of erythema gyratum repens has not been identified.
  • Different theories suggest that EGR etiology is stemmed from an immunologic reaction.
  • There is strong evidence of the association of EGR and systemic neoplasm proofed by the improvement of the skin lesions after the neoplasm treatment. However, that association doesn't mean causation.

Differentiating Erythema Gyratum Repens from Other Diseases

  • EGR has a narrow differential diagnosis. It has to be differentiated from Reactive gyrate erythematous eruptions, such as:
    • Reactive (figurate or gyrate) erythemas that are associated with malignancy include:
      • Erythema annulare centrifugum (EAC)
      • Necrolytic migratory erythema (NME)
    • Reactive (figurate or gyrate) erythemas that are not associated with malignancy include:
      • Erythema marginatum rheumaticum
      • Erythema chronicum migrans   
      • Familial annular erythema
      • The carrier state of chronic granulomatous disease
      • Subacute cutaneous lupus erythematosus
      • Neonatal lupus erythematosus


Reactive (figurate or gyrate) erythemas that are associated with malignancy
Reactive erythema

(figurate/Gyrate)

Paraneoplastic

syndrome?

Associated

neoplasms

Other associations Skin lesions First described by Incidence Demographics Subgroups Histopathology Pathogenesis Clinical symptoms Lab finding    Other evaluation Treatment    Prognosis
Erythema gyratum repens (EGR) Yes 84%

Not obligatory

Lung cancer    

Esophageal cancer   

Breast cancer

Metastatic cancer with an unknown origin

Cervical, stomach, and pharyngeal cancer (less common)

Tuberculosis

CREST syndrome

(calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia).

Migratory annular and configurate erythematous bands

that form concentric rings

 

Wood grain scaly appearance

scale follows the leading edge of the bands

Eruption migrates more rapidly, 1cm/d   


Cover the trunk and proximal extremities, sparing the hands, feet, and face. Can eventually involve the face

Gammel in 1952     Very rare Caucasian

Male: female ratio is 2: 1

Average age was 62 years.

Nonspecific

moderate perivascular lymphohistiocytic infiltrate   

Mild focal spongiosis

parakeratosis   

Eosinophils and melanophages have also been reported in the dermal infiltrate   

Not fully known

but theories

relate it to immunologic mechanisms.

Skin lesions, weight loss, fatigue, fever, and anorexia

No specific laboratory changes

Eosinophilia has been reported


Decreased T lymphocytes and increased B lymphocytes observed in an EGR patient with increased luteinizing hormone and follicle-stimulating hormone as well as decreased serum levels of C3   

Normal percentages of B and T lymphocytes and normal T-cell function were reported in an EGR patient without cancer.

Extensive evaluation for possible cancer

CBC,CMP, imaging as CT chest or abdomen

EGR patients with underlying malignancies had cancers associated with tobacco abuse.

Identification and treatment of the underlying condition (eg. resection of the tumor) Skin manifestations can be improved within 48 hours of the resection of the underlying tumor

The improvement sometimes can temporary with recurrence of the skin lesions specially in cases of metastasis

Death can occur any time dending on the type and location of tumoe rnd the timingg f its discovery

Erythema annulare centrifugum (EAC) Yes Only a minority of patients   No particular type of cancer appears to predominate 

Mutinous ovarian carcinoma   

Bronchial carcinoma   

Myeloma   


Infections

Allergic reactions to drugs  

Migratory annular and configurate erythematous

or polycyclic lesions

Urticarial in appearance," ringed, arcuate figures"

Eruption migrate at a slower rate (2 -3 mm/d) reaching up to 10 cm in diameter with central clearing.

Cover only a small percentage of the total body surface 

Darier 1916
Uncommon but not rare No tendency for EAC to favor any age, race, or sex. Deep: Firm border, rarely pruritic, no scales

Superficial: indistinct scaly border , usually pruritic,

Deep form:

Mononuclear, perivascular infiltrate in the middle and lower portions of the dermis (coat sleeve-like configuration)

Infiltrate is primarily of lymphocytes, but eosinophils are occasionally present

Extravasation of erythrocytes is associated with endothelial swelling   

No epidermal changes   

Superficial:

more non-specific

slight superficial perivascular lymphohistiocytic infiltrate   

Focal parakeratosis and mild spongiosis with microvesiculation


No specific laboratory changes

Eosinophilia of the peripheral blood, as well as tissue, can be observed in EAC associated with a drug reaction or parasitic infection   

Decreased T lymphocytes and increased B lymphocytes   

Evaluation for possible infection or drug reaction (prescribed and non-prescribed)

complete blood count, urinalysis, and routine serum liver and kidney function tests.

Identification and treatment of the underlying condition (eg. resection of the tumor) Lesions disaapears after the underlying etiology is managed (allergy, infection, malignancy)


if no underlying cause, lesions can recur after discontinuation of the supportive treatment.

Necrolytic migratory erythema (NME) Yes The first presenting symptom in

70% of patients with glucagonoma syndrome (2)

Obligatory paraneoplastic syndrome (2)

NME is the hallmark of glucagonoma (pancreatic neuroendocrine tumors (PNETs) (glucagonoma) (3) No other association but it can be misdiagnosed as contact dermatitis

or intertrigo, inverse psoriasis, zinc deficiency, and other nutritional deficiencies

migratory circinate erythema/plaques with areas of necrosis and sloughing (3)

Crusted  Erythematous scaly plaques with centrifugal growth

Spontaneous exacerbation and remission periods without knowing what the trigger is

Perineum, distal extremities, lower abdomen, and face are the most commonly affected sites.

Becker et al. in 1942 was the first to describe the association


Wilkinson in 1973 was the first who named it.

Rare

Only 2,705 cases

in the US of pancreatic neuroendocrine tumors in a period of 28 years

with glucagonomas


Only 1.3% of these neoplasms

Combined with glucagonoma syndrome


An estimated global incidence of 1 case per 20 million people (3)

Paleness and spongiosis of the upper layer of the epidermis.



A perivascular lymphocytic and histiocytic infiltrate

Necrotic keratinocytes are common and can lead to erosions, crusting and scaling

Not fully clarified but attributed to zinc deficiency and hypoaminoacedemia as Increased glucagon increases gluconeogesis.


Although NME can be the first symptom of glucagonoma, high glucagon levels cant explain the skin manifestations.

Weight loss, anemia, diabetes, diarrhea, and stomatitis. increased glucagon level (3) Evaluation of the associated tumor:

CT or MRI abdomen


Selective visceral angiography to localize the tumor


Positron Emission tomography (PET)

Octreotide scintigraphy

Identification and treatment of the underlying condition (eg. resection of the tumor) Due to the difficulty of NME recognition, and its association with glucagonoma, diagnosis is usually delayed(3)


NME usually resolved after the resection and treatment of the pancreatic tumor, eg 10 days after tumor resection

Early recognition is crucial for better diagnosis

Epidemiology and Demographics

  • EGR is a rare dermatologic disease, usually associated with paraneoplastic neoplasm

Age

  • The average age of onset of EGR is in the seventh decade of life (65 years old)

Gender

  • The male to female ratio is 2:1

Race

  • EGR commonly affects Caucasians

Risk Factors

  • There are no established risk factors for EGR

Screening

  • There are no screening tests for EGR.
  • Screening for internal malignancy should be done immediately after EGR is diagnosed.

Natural History, Complications, and Prognosis

  • The majority of patients with EGR presents with severely pruritic erythematous skin lesions that appear several months prior to the malignancy diagnosis [1]
  • If the underlying malignancy left untreated, the debilitating pruritus could persist until the patient dies [1]
  • Prognosis depends on the type of the underlying tumor and the probability of its treatment. It depends on the time of the EGR onset and the neoplasm discovery. The course and prognosis of EGR can be one of the following:
    • Complete cure of the skin eruption and pruritus after removal and treatment of the internal neoplasm
    • Temporary improvement then recurrence of the eruption (specially in cases of metastasis)
    • No effect of the tumor treatment on the course of EGR
    • Death can occur few weeks after the discovery of the malignancy, few months, or four years as in Gammel's patient.

Diagnosis

Diagnostic Study of Choice

  • EGR is mainly diagnosed clinically by its characteristic skin lesions.
  • It is considered as a cutaneous marker of malignancy with high specificity so physicians shouldn't miss its unique clinical skin presentation.

History and Symptoms

  • The universal symptoms of EGR are:
    • Skin eruptions
    • Intense pruritus
  • Other symptoms related to the associated internal malignancy are:
    • Weight loss
    • Anorexia
    • Fatigue
    • Fever
    • Many patients with EGR and malignancy had a history of tobacco smoking
    • some patients with EGR and malignancy have a family history of neoplasm

Physical Examination

  • Patients with EGR can be ill-appearing and lethargic
  • Thorough physical exam should be done to look for signs of malignancy as lymph node enlargements, mass, abdominal distension, shortness of breath, pleural effusion,or papilloedema.
  • The rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular.
  • The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained.
  • The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expand as fast as a cm a day.
  • Bullae can also form from within the areas of erythema [1]

Laboratory Findings

  • There are no diagnostic laboratory findings associated with EGR.
  • Eosinophilia is observed in 60% of cases [1]
  • Evaluation to exclude systemic involvement:
    • CBC, CMP, urine analysis, LFT, guaiac stool test, serum protein electrophoresis

Imaging Findings

  • There are no imaging findings associated with EGR.
  • Imaging of the chest and abdomen could show malignancy findings.

Other Diagnostic Studies

  • Direct immunofluorescence in some cases shows patterns of IgG, C3, and C4 at the basement membrane [1]
  • The histopathologic features of EGR is non-specific.
  • Biopsy specimens show the following:
    • Acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis.
    • Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen [1]
  • Thorough paraneoplastic workup includes:
    • Computed tomography of thorax, abdomen, and pelvis
    • Positron emission tomography/computed tomography
    • Upper and lower gastrointestinal endoscopy
    • Tumor markers
    • Blood tests including lactate dehydrogenase and QuantiFERON to exclude tuberculosis.

Treatment

Medical Therapy

  • There is no treatment for EGR; the mainstay of therapy is supportive care and treating the underlying condition [1]
  • Various dermatologic and immunosuppressive therapies have been used to treat EGR.
  • Systemic steroids are frequently ineffective.
  • Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations.
  • Improvement of EGR, and its associated intense pruritus depends on recognition and treatment of the underlying malignancy.
  • Chemotherapy can be used to treat the internal malignancy.

Surgery

  • Surgical resection of the internal tumor could be recommended as part of the management of EGR.

Prevention

  • There are no primary preventive measures available for [disease name].

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Gore M, Winters ME (2011). "Erythema gyratum repens: a rare paraneoplastic rash". West J Emerg Med. 12 (4): 556–8. doi:10.5811/westjem.2010.11.2090. PMC 3236141. PMID 22224159 PMID: 22224159 Check |pmid= value (help).